Aclarion Inc. (ACON)
Bid | 8 |
Market Cap | 5.02M |
Revenue (ttm) | 49.29K |
Net Income (ttm) | -6.27M |
EPS (ttm) | -5658.42 |
PE Ratio (ttm) | n/a |
Forward PE | -0.05 |
Analyst | Hold |
Ask | 9.35 |
Volume | 37,914 |
Avg. Volume (20D) | 208,502 |
Open | 8.70 |
Previous Close | 8.58 |
Day's Range | 8.50 - 8.63 |
52-Week Range | 7.26 - 6241.05 |
Beta | 1.08 |
About ACON
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclari...
Analyst Forecast
According to 2 analyst ratings, the average rating for ACON stock is "Hold." The 12-month stock price forecast is $481, which is an increase of 5473.58% from the latest price.
Stock ForecastsEarnings Surprise
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription

2 months ago · prismmediawire.com
Aclarion Announces CLARITY Trial for Nociscan Now Fully FundedBroomfield, CO, February 4, 2025 – PRISM MediaWire – Aclarion, Inc.

2 months ago · prismmediawire.com
Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine ConferenceBROOMFIELD, Colo., January 31, 2025 – PRISM MediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprieta...